GlassScriptPhysician profile
Richard A Gayle
NPI 1033179395
$4,267.92
in general payments reported to CMS, 2019-2025
31 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $340 · 2021: $526 · 2022: $473 · 2023: $585 · 2024: $410 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.53 |
| Education | $307.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $543.27 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $502.60 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $367.99 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $359.57 | 2019-2024 | Auryxia, Vafseo |
| Mallinckrodt Hospital Products INC. | $321.67 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $313.38 | 2019-2025 | Veltassa |
| Amgen INC. | $305.66 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $268.95 | 2021-2025 | |
| Ardelyx, INC. | $206.81 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $183.20 | 2019-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $148.14 | 2024-2025 | Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.91 | 2024-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $63.37 | 2025 | Yorvipath |
| Travere Therapeutics, INC. | $63.30 | 2023-2025 | Filspari |
| Shield Therapeutics INC | $58.43 | 2023-2025 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $52.07 | 2025 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $43.65 | 2025 | Venxxiva |
| Vanda Pharmaceuticals INC. | $43.32 | 2020 | |
| Glaxosmithkline, LLC. | $38.56 | 2020-2023 | Benlysta |
| Baxter Healthcare | $36.79 | 2019 | |
| Horizon Therapeutics Plc | $34.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.93 | 2023-2025 | |
| Cormedix INC. | $31.23 | 2025 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2021-2023 | Gattex |
| Outset Medical INC | $24.09 | 2023 | |
| Kyowa Kirin, INC. | $20.40 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.29 | 2021 | |
| Novo Nordisk INC | $15.73 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $15.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $14.32 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gayle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.